Severe autoimmune-mediated neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and ...

Mitochondrial health testing is becoming the go-to tool for tracking biological age and optimizing energy, metabolism, and ...

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for ...

The cure to cancer may not be hidden in some drug or chemical but within our own body. A team of Chinese researchers recently ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

T-cell therapy for rheumatologic disease is now expanding out of academe into the commercial space, with encouraging new data ...

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...